-
Notable Insider Buys Of The Past Week: AT&T, GoodRx, Opendoor Technologies And More
Sunday, May 23, 2021 - 10:24am | 993Read More...Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A couple of chief executive officers and a president were among the insiders buying shares this past week. A leading telecom that just announced a major deal was among companies...
-
Last Week's Notable Insider Buys: Cboe, IBM, Xerox And More
Saturday, November 7, 2020 - 3:07pm | 915Read More...Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Activist investor Carl Icahn added to a stake last week. Financial companies and an options exchange operator saw insiders buying too. Conventional wisdom says that insiders and 10% shareholders...
-
Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors
Monday, July 16, 2018 - 7:45am | 540Read More...Insider buying can be an encouraging signal for potential investors. An activist investor took the next step in acquiring his target. Also, a couple of return buyers stepped up to the buy windows last week. Conventional wisdom says insiders and 10 percent owners really only buy shares of a...
-
Esperion Therapetuics Surges 13%
Wednesday, March 2, 2016 - 12:45pm | 218Read More...Shares of Esperion Therapeutics Inc (NASDAQ: ESPR) surged higher by more than 13 percent on Wednesday after the company's director, Gilbert Omenn, disclosed an insider purchase of 5,000 shares of company stock. Omenn disclosed in a regulatory filing he bought 5,000 shares of Esperion's stock on...
-
4 SMID-Cap Biotechs Barclays Just Confessed It Loves
Thursday, May 21, 2015 - 9:00am | 550Read More...In a new research note, Barclays analysts said that the run in biotech stocks is not over. In fact, the firm initiated coverage on four names, three of which it started with Overweight ratings. On that Overweight side, Barclays likes Alkermes Plc (NASDAQ: ALKS), Esperion Therapeutics Inc (...
-
Pro: Esperion Therapeutics Shares Could Double
Saturday, March 21, 2015 - 3:27pm | 217Read More...Esperion Therapeutics Inc (NASDAQ: ESPR), whose shares are up 50 percent in the past week, might see a further doubling in price, Stephen L. Weiss told Benzinga on Friday. Weiss is managing partner of Short Hills Capital Partners and a regular CNBC Contributor. "It's been great. I...
